Kadmon

Former Kadmon consultant pleads guilty to insider trading ahead of Sanofi buyout
Former Kadmon consultant pleads guilty to insider trading ahead of Sanofi buyout
Fierce Pharma
Sanofi
Kadmon
insider trading
legal
DOJ
Flag link:
Sanofi's latest analysis of Rezurock can inform future research, company says
Sanofi's latest analysis of Rezurock can inform future research, company says
Fierce Pharma
Sanofi
Kadmon
M&A
graft vs host disease
Rezurock
Flag link:
Sanofi cuts 2 dozen Kadmon staffers after $1.9B buyout: filing
Sanofi cuts 2 dozen Kadmon staffers after $1.9B buyout: filing
Fierce Pharma
Sanofi
Kadmon
layoffs
Flag link:
The top 10 biopharma M&A deals in 2021
The top 10 biopharma M&A deals in 2021
Fierce Pharma
M&A
CSL
Vifor
Jazz Pharmaeuticals
GW Pharma
Novo Nordisk
Dicerna
Horizon Therapeutics
Viela Bio
Perrigo
HRA Pharma
Sanofi
Kadmon
Merck
Acceleron
Pfizer
Arena Pharmaceuticals
Translate Bio
Trillium Therapeutics
Amgen
Five Prime Therapeutics
Flag link:
Sanofi acquires Kadmon for $1.9 billion, adding transplant medicine drug
Sanofi acquires Kadmon for $1.9 billion, adding transplant medicine drug
Stat
Sanofi
Kadmon
M&A
transplant medicine
graft vs host disease
Flag link:
FDA Action Alert: Cara/Vifor, Kadmon, BMS, Merck/Eisai
FDA Action Alert: Cara/Vifor, Kadmon, BMS, Merck/Eisai
BioSpace
FDA
Cara Therapeutics
Vifor Pharma
Korsuva
Kadmon
belumosudil
Bristol Myers Squibb
Opdivo
Merck
Eisai
Keytruda
Flag link:
Kadmon's Rezurock scores surprise FDA nod in chronic graft-versus-host-disease
Kadmon's Rezurock scores surprise FDA nod in chronic graft-versus-host-disease
Fierce Pharma
Kadmon
Rezurock
graft vs host disease
FDA
belumodsil
Flag link:
FDA delays Kadmon’s priority review as apparent clampdown continues
FDA delays Kadmon’s priority review as apparent clampdown continues
Endpoints
Kadmon
FDA
priority review
belumodsil
graft vs host disease
Flag link:
Kadmon’s graft-versus-host disease med on track for 2020 filing
Kadmon’s graft-versus-host disease med on track for 2020 filing
Fierce Biotech
Kadmon
belumodsil
graft vs host disease
clinical trials
Flag link:
Kadmon drops detailed look at cGVHD data; analysts see 'underappreciated potential'
Kadmon drops detailed look at cGVHD data; analysts see 'underappreciated potential'
Fierce Biotech
Kadmon
KD025
cGVHD
clinical trials
Flag link:
Upcoming events – key tests approach for Kadmon and Surface
Upcoming events – key tests approach for Kadmon and Surface
EP Vantage
Kadmon
graft vs host disease
Surface Oncology
SRF373/NZV930
Flag link:
Rough public start for biotech founded by ex-con, as CEO fumes at ‘vicious’ press
Rough public start for biotech founded by ex-con, as CEO fumes at ‘vicious’ press
Stat
Kadmon
Sam Waksal
ImClone
Flag link:
Banned ImClone founder plans IPO for new venture
Banned ImClone founder plans IPO for new venture
CNBC
ImClone
Sam Waksal
IPOs
Kadmon
Flag link:
Sam Waksal, A Hepatitis C Medicine And An FDA Warning Letter
Sam Waksal, A Hepatitis C Medicine And An FDA Warning Letter
Pharmalot
hepatitis C
FDA
Ribasphere
Kadmon
Flag link:
ImClone’s Waksal Back in Biotech With Plans for Spinouts
ImClone’s Waksal Back in Biotech With Plans for Spinouts
Bloomberg
ImClone
Sam Waksal
biotech
Kadmon
Flag link:
ImClone Founder Waksal Forming New Biotech Venture
ImClone Founder Waksal Forming New Biotech Venture
TheStreet.com
insider trading
ImClone
Kadmon
Flag link: